Beresford Funds ICAV (Registered Number C45619) Annual Report and Audited Financial Statements For the financial year ended 31
Beresford Funds ICAV (Registered Number C45619) Annual Report and Audited Financial Statements For the financial year ended 31
![BusinessWire - Celgene Corporation (CG3) FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation | ResearchPool BusinessWire - Celgene Corporation (CG3) FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation | ResearchPool](https://mms.businesswire.com/media/20170801006281/en/604221/4/AML_infographic_8117---FINAL.jpg)